Publications by authors named "JoAnn Peters"
Article Synopsis
- PD-1 inhibitors show limited effectiveness on their own for treating hepatocellular carcinoma (HCC), but a new personalized therapeutic cancer vaccine (PTCV) may boost their efficacy by enhancing immune responses against tumors.
- In a study, a DNA plasmid PTCV combined with pembrolizumab was tested on patients with advanced HCC; the treatment was found to be relatively safe with manageable side effects and showed a 30.6% objective response rate.
- The study observed that patients with more neoantigens from the vaccine had better clinical responses, with immune profiling revealing a strong T cell response directed at tumor cells, supporting the vaccine's potential as a viable therapeutic approach.
Background: Late middle age (LMA), is a watershed between youth and old age, with unique physical and social changes and declines in vitality, but a desire to remain active despite increasing comorbidity. While post-injury outcomes in the elderly are well studied, little is known regarding LMA patients. We analyzed the injured LMA population admitted to a rural, regional Level 1 Trauma Center relative to outcomes for both younger and older patients.
View Article and Find Full Text PDFObjectives: After rural injury, evaluation at local hospitals with transfer to regional trauma centres may delay definitive care. This study sought to determine the impact of such delays on outcomes in patients with TBI within a mature regional trauma system.
Methods: The ETMC Level 1 Trauma registry was queried from 2008-2013 for patients with blunt TBI, aged ≥ 18 and admitted ≤ 24 hours from injury and stratified them as 'transfer' vs 'direct' admission.